

Anti-amyloid therapy in AD – Structured MRI Report ARIA Monitoring scan

Purpose of scan

1. To monitor asymptomatic ARIA-E or ARIA-H in routine follow up
2. To detect or exclude ARIA-E or ARIA-H in symptomatic patient
3. To monitor change in ARIA-E and ARIA-H over time

Relevant clinical information

APOE ε4 status (if known): ☐ Unknown ☐ Non-carrier ☐ Carrier (heterozygous) ☐ Carrier (homozygous)

Drug / Treatment: ☐ Lecanemab ☐ Donanemab ☐ Other: _____

Purpose of scan: ☐ Routine monitoring ☐ Symptom-triggered (type of symptoms: _____) ☐ Follow-up ARIA

If follow-up: monitoring visit number (e.g. Week 24): _____

Baseline MRI date: _____

Previous MRI date: _____

Previous ARIA episode: ☐ None ☐ Yes, if yes: date or week of onset: _____

Technique

Field strength: ☐ 1.5T ☐ 3T ☐ other.....

FLAIR: ☐ 2D ☐ 3D

Hemosiderin-sensitive sequence: ☐ SWI ☐ T2* GRE

DWI: ☐ Yes ☐ No

Technique with identical parameters to previous scan: ☐ Yes ☐ No, explain: _____

Image quality: ☐ Adequate ☐ Limited (specify:) _____

Motion artefacts: ☐ None ☐ Mild ☐ Moderate ☐ Severe (specify effect): _____

Additional Sequences Performed: _____

Findings – ARIA-E (Edema/Effusion)

Presence: ☐ None ☐ Possible ☐ Definite

Number of foci: ____

Location(s): _____

Laterality: ☐ Unilateral ☐ Bilateral

Pattern: ☐ Parenchymal edema ☐ Sulcal effusion ☐ Both

Cortical swelling / sulcal effacement: ☐ None ☐ Present

Largest lesion size: ☐ ____ mm (longest diameter on FLAIR in any direction) ☐ not measurable (if only sulcal)

Evolution vs previous: ☐ New ☐ Increased ☐ Decreased ☐ Mixed (both increase and decrease) ☐ Resolved ☐ Stable

Associated mass effect: ☐ None ☐ Minimal ☐ Mild ☐ Moderate

Associated enhancement (if contrast used): ☐ Yes ☐ No

ARIA-E Severity (lookup table):

Grade	Imaging Criteria	Rating
Mild	≤5 cm in one region	☐
Moderate	5–10 cm in one region, or multiple small regions	☐
Severe	>10 cm or confluent involvement	☐

Findings – ARIA-H (Hemosiderin deposition)

Presence: ☐ None ☐ Possible ☐ Definite

Type: ☐ Microhemorrhages ☐ Superficial siderosis ☐ Both

Location(s): _____

Number of new microbleeds since last MRI: _____

Total microbleeds (current scan): _____

Total new microbleeds since baseline: _____

Cortical superficial siderosis (cSS): ☐ None ☐ Focal ☐ Disseminated, how many sulci:

Evolution vs previous: ☐ New ☐ Increased ☐ Decreased ☐ Stable

ARIA-H Severity (lookup table):

Grade	Imaging Criteria	Rating
Mild	≤4 new CMBs since baseline	☐
Moderate	5–9 new CMBs or focal cSS since baseline	☐
Severe	≥10 new CMBs or disseminated cSS since baseline	☐

Findings – Other

Restricted diffusion (DWI): ☐ None ☐ Present → specify: _____

Enhancement (if contrast used): ☐ None ☐ Present → specify pattern: _____

Other relevant findings: _____

Findings – Use of AI algorithm

Was an AI algorithm used in assessment of any of the findings: ☐ None ☐ Yes

If so, specify which findings and which algorithm: _____

Level of Diagnostic Certainty

- ☐ Definite ARIA (findings fulfill all imaging criteria)
- ☐ Possible ARIA (equivocal findings; repeat MRI advised)
- ☐ No ARIA (normal or unrelated findings)

Summary / Impression

ARIA status:

- ☐ No ARIA ☐ ARIA-E (☐ mild ☐ moderate ☐ severe) ☐ ARIA-H (☐ mild ☐ moderate ☐ severe)
- ☐ ARIA mimic, namely: _____

Evolution vs prior, ARIA-E:

- ☐ New/ first occurrence ☐ Progression ☐ Stable ☐ Partial resolution ☐ Complete resolution

Evolution vs prior, ARIA-H:

- ☐ New/ first occurrence ☐ Progression ☐ Stable

Note: Findings should be interpreted in clinical context for treatment decision-making